Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

Nakamura, Yasuhiro; Teramoto, Yukiko; Asami, Yuri; Matsuya, Taisuke; Adachi, Jun-ichi; Nishikawa, Ryo; Yamamoto, Akifumi

doi:10.1001/jamadermatol.2017.1679

Cited by 23 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This case is similar to one previously reported with nivolumab (9). This patient who received nivolumab for metastatic melanoma developed vitiligo spots along with tumour response.…”

Section: Discussionsupporting

confidence: 89%

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment

Nardin¹,

Pelletier²,

Puzenat³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

“…This case is similar to one previously reported with nivolumab (9). This patient who received nivolumab for metastatic melanoma developed vitiligo spots along with tumour response.…”

Section: Discussionsupporting

confidence: 89%

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment

Nardin¹,

Pelletier²,

Puzenat³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

“…Conversely, we had a patient who developed vitiligo on the hands, shoulder and face, and requested to stop nivolumab because the patient achieved CR; however, the patient developed PD and partial repigmentation of vitiligo simultaneously 8 months thereafter in the present study (Fig. 2, case 2), whose interim clinical course was previously reported as a case report 15 …”

Section: Discussionmentioning

confidence: 69%

“…Some cases had a previous history of unsuccessful cytotoxic chemotherapy and received nivolumab or pembrolizumab as a second‐line or later treatment. Eight melanoma patients who had been reported previously by our groups were also included in this study 12,15 . Patients with a follow‐up period of fewer than 2 months, missing radiological response assessment, and autoimmune disease or vitiligo prior to the initiation of anti‐PD‐1 antibody treatment were excluded from the study.…”

Section: Methodsmentioning

confidence: 99%

Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study

Matsuya

Nakamura

Matsushita

et al. 2020

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Vitiligo is an autoimmune disorder resulting from the destruction of melanocytes. Several reports indicate the association between vitiligo and treatment response in advanced melanoma during immunotherapy. It has not been investigated, however, if an increase of vitiligo while on treatment with anti-programmed death 1 (PD-1) antibodies is associated with more durable responses. The aim of this study is to evaluate the correlation between the vitiligo dynamics and clinical efficacy of anti-PD-1 antibodies. This study included advanced melanoma patients who were treated with nivolumab or pembrolizumab and developed vitiligo thereafter. Correlation between vitiligo expansion (defined as an increase of lesion size at two separate time points at least 4 weeks apart) as well as vitiligo extent (body surface area [BSA] affected) and clinical efficacy based on response rate, progression-free survival and overall survival was assessed. We retrospectively reviewed 29 patients. The median time from the initiation of anti-PD-1 antibody to vitiligo onset was 4.3 months in patients who showed a response and 5.5 months in patients who showed no response (P = 0.31). Twelve patients showed vitiligo expansion, and in nine of these patients, vitiligo increased to grade 2 (covering ≥ 10% BSA). Vitiligo expansion and grade 2 vitiligo showed no improvement in treatment response (P = 0.59 and 0.25) but were associated with prolonged progression-free survival (P = 0.019 and 0.04). Grade 2 vitiligo also showed a trend for prolonged overall survival (P = 0.07). Trend of expansion and larger vitiligo extent may be predictive factors of prolonged survival during anti-PD-1 antibody in melanoma patients.

show abstract

“…In one melanoma patient, a complete response to immunotherapy was achieved with the contemporaneous development of leukoderma. After 8 months from therapy conclusion, repigmentation occurred with the appearance of brain and liver metastases [77]. However, in an animal model of melanoma-associated leukoderma [45,63], generation of skin-resident memory T cell responses to melanoma naturally occurred as a result of leukoderma development that played a key role in perpetuating anti-tumor immunity [78].…”

Section: Check-point Inhibitorsmentioning

confidence: 99%

Melanoma and Vitiligo: In Good Company

Failla

Carbone

Fortes

et al. 2019

IJMS

View full text Add to dashboard Cite

Cutaneous melanoma represents the most aggressive form of skin cancer, whereas vitiligo is an autoimmune disorder that leads to progressive destruction of skin melanocytes. However, vitiligo has been associated with cutaneous melanoma since the 1970s. Most of the antigens recognized by the immune system are expressed by both melanoma cells and normal melanocytes, explaining why the autoimmune response against melanocytes that led to vitiligo could be also present in melanoma patients. Leukoderma has been also observed as a side effect of melanoma immunotherapy and has always been associated with a favorable prognosis. In this review, we discuss several characteristics of the immune system responses shared by melanoma and vitiligo patients, as well as the significance of occurrence of leukoderma during immunotherapy, with special attention to check-point inhibitors.

show abstract

Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

Cited by 23 publications

References 6 publications

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment

Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study

Melanoma and Vitiligo: In Good Company

Contact Info

Product

Resources

About